Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

886 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial.
Vernazza P, Wang C, Pozniak A, Weil E, Pulik P, Cooper DA, Kaplan R, Lazzarin A, Valdez H, Goodrich J, Mori J, Craig C, Tawadrous M. Vernazza P, et al. Among authors: lazzarin a. J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):171-9. doi: 10.1097/QAI.0b013e31827a2ba2.. J Acquir Immune Defic Syndr. 2013. PMID: 23328090 Clinical Trial.
A controlled trial of zidovudine in primary human immunodeficiency virus infection.
Kinloch-De Loës S, Hirschel BJ, Hoen B, Cooper DA, Tindall B, Carr A, Saurat JH, Clumeck N, Lazzarin A, Mathiesen L, et al. Kinloch-De Loës S, et al. Among authors: lazzarin a. N Engl J Med. 1995 Aug 17;333(7):408-13. doi: 10.1056/NEJM199508173330702. N Engl J Med. 1995. PMID: 7616989 Free article. Clinical Trial.
A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.
Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, Bisset LR, Fischer M, Vernazza P, Bernasconi E, Battegay M, Ledergerber B, Günthard H, Howe C, Weber R, Perrin L; Swiss HIV Cohort Study. Opravil M, et al. Among authors: lazzarin a. J Infect Dis. 2002 May 1;185(9):1251-60. doi: 10.1086/340312. Epub 2002 Apr 1. J Infect Dis. 2002. PMID: 12001042 Free article. Clinical Trial.
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial.
Mazzotta F, Lo Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, Lazzarin A, Angarano G, Maserati R, Gianotti N, Ladisa N, Quiros-Roldan E, Rinehart AR, Carosi G; Genotipo-Fenotipo di Resistenza (GenPheRex) Group of the Italian Management Standardizzato di Terapia Antiretrovirale (MASTER) Cohort. Mazzotta F, et al. Among authors: lazzarin a. J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):268-80. doi: 10.1097/00126334-200303010-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12626886 Clinical Trial.
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M; TORO 2 Study Group. Lazzarin A, et al. N Engl J Med. 2003 May 29;348(22):2186-95. doi: 10.1056/NEJMoa035211. N Engl J Med. 2003. PMID: 12773645 Free article. Clinical Trial.
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, Jemsek J, Rivero A, Rozenbaum W, Schrader S, Sension M, Vibhagool A, Thiry A, Giordano M. Squires K, et al. Among authors: lazzarin a. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1011-9. doi: 10.1097/00126334-200408150-00003. J Acquir Immune Defic Syndr. 2004. PMID: 15247553 Clinical Trial.
886 results